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Background: In the US, approximately 50% of hepatocellular carcinoma (HCC) is caused by hepatitis-C virus (HCV)
infection. The molecular mechanism of a malignant transformation of hepatocyte induced by HCV infection is still
largely unclear. There are several clinical and pathological staging systems for HCC, but none of them include biological
parameters as predictors for prognosis and there has not been a standardized molecular classification of HCC. To
understand the underlying pathogenic genetic alterations in HCV-associated HCC and aid in molecular classification of
HCC and patient prognosis, microarray analysis of DNA copy number alterations in HCC were conducted using whole
genome microarray with DNA from formalin-fixed paraffin-embedded (FFPE) specimens of both cancer tissues and
paired nearby cirrhotic non-neoplastic tissues.
Results: Our results show that the most common chromosomal aberrations (>5 Mb) observed in HCC were
chromosomal gains of 1q (80%), 8q (60%), 7q (40%), 5p (33%), 7p (33%), Xq (33%), 5q (27%), and Xp (20%), as well as
chromosome losses of 17p (40%), 4q21.21-q26 (33%), 8p (33%), 1p36.11-pter (20%), and 9p (20%). Statistically significant
smaller copy number alterations (3.9 kb to 644 kb) were identified using STAC algorithm, including losses of FGFR3,
RECQL4, NOTCH1, PTEN, TSC2, and/or ASPSCR1 and gains of ETV1and/or MAF. Correlation analysis between genetic data
and pathological data showed that gain of 1q21.1-q23.2 and gain of 8q11.1q13.1 are significantly associated with grade
2–4 and moderately or poorly differentiated HCCs, and gain of chromosome 5q was significantly associated with HCCs
with vascular invasion, while gain of chromosome 7q is significantly associated with stage I HCCs.
Conclusions: This study has provided a detailed map of genomic aberrations occurring in HCV-associated HCC
and has suggested candidate genes. In addition, gene enrichment analysis on the recurrent abnormal regions indicated
NF- kappaB and BMP signaling pathways in HCC development and progression. This study demonstrated that genomic
microarray test can be used to distinguish HCC from non- neoplastic cirrhotic nodules and to identify prognostic
factors associated with HCC progression using pathologically characterized FFPE samples. Our data support the
utility of genomic microarray test for the diagnosis, risk stratification, and pathogenic studies of HCC.
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Hepatocellular carcinoma (HCC) is one of the most
common malignant neoplasm and represents the third
leading cause of cancer-related death worldwide [1,2].
The incidence of HCC is increasing in the United
States and Europe, mostly because of the high preva-
lence of hepatitis C virus (HCV) infection [3,4]. The
molecular mechanism of a malignant transformation
of hepatocyte induced by HCV infection is still largely
unclear. The lack of good cellular and animal models
of HCV hepatocarcinogenesis further hampers the un-
derstanding of the underlying mechanisms. Given that
HCV is an RNA virus which replicates in the cyto-
plasm and has little potential for integration of its
genome into host DNA [5,6], liver cirrhosis has gener-
ally been considered a prerequisite for HCV-infected
livers to develop HCC. The pathogenesis of HCC in
chronic HCV infection is generally accepted as chronic in-
flammation and injury, which leads to fibrosis with even-
tual progression to cirrhosis and subsequent development
of HCC [7]. There are several clinical and pathological sta-
ging systems for HCC, but none of them include bio-
logical parameters as predictors for prognosis [8], and
there has not been a standardized molecular classification
of HCC. The low efficacy of systemic chemotherapies for
HCC (<40%) [7] encourage intensive investigation to iden-
tify the molecular mechanisms implicated in the carcino-
genesis of HCV associated HCC, an area of great need.
This study aimed to determine the patterns of recur-
rent genetic alterations and common pathways involved
in the development and progression of HCV-associated
HCC using high resolution genomic microarray analysisTable 1 Summary of the patient demographics, clinical and p
HCC





HCC01 45 m caucasian HCV na* ye
HCC02 57 m Asian HCV na ye
HCC03 57 m caucasian HCV na ye
HCC04 49 m unknown HCV na ye
HCC05 65 m unknown HCV 2a ye
HCC06 50 m caucasian HCV na ye
HCC07 56 m caucasian HCV 2b ye
HCC08 62 m caucasian HCV na ye
HCC09 51 m caucasian HCV 1a ye
HCC10 60 m caucasian HCV 3 ye
HCC11 53 m caucasian HCV na ye
HCC12 57 m unknown HCV na ye
HCC13 48 m Asian HCV na ye
HCC14 66 m Native American HCV na ye
HCC15 51 m caucasian HCV 1a ye
*na - not available.and the correlations of genetic alterations with tumor
phenotype, clinical presentation and outcome to im-
prove the identification of risk factors in molecular HCC
subtypes. Although genomic studies for characterization
of DNA copy number alterations of HCV-associated
HCC [9,10] or HCC due to various or unspecified etiolo-
gies [11-14] have been conducted, these studies used ei-
ther conventional comparative genome hybridization
(CGH) on metaphase cells or low density Bacterial Arti-
ficial Chromosome (BAC) clone array-based CGH ana-
lysis, therefore, submicroscopic and small copy number
alterations could be undetected. In addition, no correl-
ation analysis between genetic alterations and clinical
and pathological data of HCC was conducted to define
clinically relevant subtypes for prognosis. Furthermore,
all the specimens used in this study were formalin-fixed
paraffin-embedded (FFPE) HCC tissues, demonstrating
the feasibility of whole genome microarray analysis using
FFPE HCC specimens, and paired non-neoplastic cir-
rhotic nodules were also examined for comparison.
Results
Clinical and pathologic characterizations of HCC
specimens
A total of 15 cases from which the paraffin blocks con-
tained enough tumors for DNA isolation were included.
The patients’ demographics, clinical and pathologic fea-
tures of the specimens are summarized in Table 1. The
age of these patients ranged from 45 to 67 years with an
average of 56 years. The tumor size ranged from 1 to 4 cm
with an average of 2.2 cm. Pathological examinations of











s G2 moderate T1NxMx 1.3 no
s G4 poor T1NxMx 2.7 no
s G2 moderate T1NxMx 2 no
s G4 poor T3NxMx 3 yes
s G3 moderate T2N0Mx 2.4 no
s G3 moderate T2N0Mx 2.5 yes
s G1 well T1N0Mx 1.5 no
s G2 moderate T2NxMx 2.1 no
s G1 well T1NxMx 1.8 no
s G3 moderate T1NxMx 1.7 yes
s G3 moderate T2NxMx 3 no
s G1 well T1N0Mx 2.3 yes
s G2 moderate T1NxMx 1 no
s G1 well T1NxMx 3 no
s G1 well T1NxMx 1.5 no
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for hepatitis B co-infection by serology or viral DNA test,
and occult hepatitis B was also excluded by PCR. Due to
the retrospective nature of the study, only a subset of
these specimens has HCV genotype data.
Whole genome microarray analysis using FFPE specimens
DNA was extracted from FFPE tissues of 16 HCCs and
10 paired non-neoplastic cirrhotic liver tissues. Except
for one HCC specimen, microarray analysis for copy
number changes were successful for 15 HCC specimens
and 10 paired non-neoplastic cirrhotic liver tissues, giv-
ing a 96.2% successful rate for microarray analysis using
FFPE specimens. As an example, HCC01 showed a copy
gain of the long arm of chromosome 1 (1q) (Table 1,
Figure 1A,) and amplified regions containing multiple
genes on 1q (Figure 1B). Tumor cellularity, the relative
proportion of tumor and normal cells in a sample, af-
fects the sensitivity of copy number detection, and can
be estimated based on the review of H & E stained slide
by the pathologist. In addition, the log2 ratio and copy
number line fit plots by Cytogenomics can also be used
to indicate clonal diversity and estimate tumor cellularity
for each clone. For instance, the tumor cellularity in
HCC01 was estimated to be approximately 57% based
on the pathologist’s review of the H & E stained slide
and the log2 ratio and copy number line fit plot by Cyto-
genomics. In addition, no clonal diversity in HCC01 was
indicated by the log2 ratio and copy number line fit plot.Figure 1 Whole genomic profile of HCC using formalin-fixed paraffin-em
(HCC01, Table 1), and the zoomed in area is in the black circle. B. Amplified g
of PIK3C2B and MDM4 are indicated with a circle. X-axis represents genomic i
Y-axis represents log2Ratios.Based on the values of log2 ratios and 57% tumor cellu-
larity, the numbers of copy gains in the amplified regions
on 1q of HCC01 were estimated to be four and seven
copies (including gains of MDM4 and PIK3C2B), re-
spectively (Figure 1B).
Recurrent copy number alterations in HCC
Clonal chromosomal abnormalities were detected in all
HCC samples but not in their paired non-neoplastic tis-
sues. Accumulative and individual chromosomal imbal-
ances in the HCV-HCC genomes are summarized in
Figure 2. Recurrent copy gains and losses of genomic re-
gions that were larger than 5 Mb in the HCV-HCC
specimens were summarized in Table 2. The common
chromosomal aberrations (>5 Mb) observed in HCC
were chromosomal gains of 1q (80%), 8q (60%), 7q
(40%), 5p (33%), 7p (33%), Xq (33%), 5q (27%), and Xp
(20%), as well as chromosome losses of 17p (40%),
4q21.21-q26 (33%), 8p (33%), 1p36.11-pter (20%), and 9p
(20%). The numbers of chromosomal imbalance larger
than 5 Mb in each case ranged from 2 to 12 copy num-
ber changes per case with 7 copy number changes per
case on average. No chromosomal aberrations were ob-
served in the 10 paired non-neoplastic cirrhotic liver tis-
sues that were available for examination.
Statistically significant smaller copy number alterations
were identified and ranged from 3.9 kb to 644 kb using
STAC algorithm implemented in Nexus 7.5 (Table 3).
Among the genes in these regions, known cancer genesbedded (FFPE) specimen. A. Genomic profile of HCV associated HCC
ene regions on 1q32.1 with one, four or seven copy gains. Gene locations
ntervals of chromosomes 1–22 (1A) or genes in amplified regions (1B).
Figure 2 Genomic profile of HCC specimens showing recurrent chromosomal gains and losses. A. The accumulative frequency (or aggregate) plot
for the HCC specimens with rate (%) labeled for the most frequent recurrent clonal chromosomal gains and losses in 15 HCV-associated HCC specimens.
Blue bars indicate gains and red bars indicate losses. B. Genomic profiles of copy number alterations in individual HCC specimens.
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cancer.sanger.ac.uk/cancergenome/projects/census/) in-
cluded losses of FGFR3, RECQL4, NOTCH1, PTEN,
TSC2, and/or ASPSCR1 and gains of ETV1 and/or MAF.
In addition, copy gain involving Androgen receptor (AR)
were observed in five of 15 HCCs analyzed.
Correlation of recurrent genetic alterations with clinical
and pathologic data
Three comparison/correlation analyses were conducted
and the difference in frequency for gains and losses in
each group are shown in Figure 3 and significant gen-
omic aberrations identified are summarized in Tables 4,
5 and 6. A subset of signature copy number alterations
associated with specific HCC pathologic features was
identified.
In comparison analysis I, five grade 1 and well differ-
entiated HCCs (A, Figure 3) were compared with ten
grade 2–4 and moderately or poorly differentiated HCCs
(B, Figure 3). Significant copy number aberrations associ-
ated with grade 1 and well differentiated HCCs are gain of
11q23.2 containing ZBTB16 and gain of 16q23.2 contain-
ing MAF (Table 4). Significant copy number aberrations
associated with grade 2–4 and moderately or poorly differ-
entiated HCCs are gain of 1q21.1-q23.2 containing 261
genes including 5 cancer genes BCL9, ARNT, TPM3,
MUC1, and NTRK1 and gain of 8q11.1q13.1 containing
76 genes including 3 cancer genes TCEA1, PLAG1, and
CHCHD7 (Table 4). In addition, gains of chromosomes 5
and X and loss of 9p were only found in grade 2–4 and
moderately or poorly differentiated HCCs although they
did not reach statistical significance (Figure 3A and B).
Gene enrichment analysis on significant common ab-
errations identified by the comparison analysis I showed
that the genes that are significantly enriched in grade
2–4 and moderately or poorly differentiated HCCs wereinvolved in positive regulation of NF-kappaB transcrip-
tion factor activity, including gains of S100A9, S100A12,
S100A8, IL6R, NTRK1, AIM2, and NLRP3 on 1q, and in
regulation of chemokine production, including gains of
DARC on 1q and SNAI2 on 8q.
Furthermore, the numbers of chromosomal imbal-
ance larger than 5 Mb in each case ranged from 2 to 6
copy number changes per case (on average 3.8 copy
number changes per case) for grade 1 and well differen-
tiated tumors when compared with 3 to 12 copy num-
ber changes per case (on average 7.1 copy number
changes per case) for grade 2–4 or moderate or poorly dif-
ferentiated tumors. The copy number variants (CNV) bur-
den in terms of average number of CNVs for each
category is significantly different with p-value of 0.023
using student’s t-test.
In comparison analysis II, ten stage I HCCs (C, Figure 3)
were compared with five stage II or III HCCs (D, Figure 3).
Significant copy number aberrations associated with stage
I tumors are gain of the long arm of chromosome 7 (7q),
gain of 7p11.2 containing EGFR, and gain of 7p21.2 con-
taining ETV1 (Table 5). Among the genes in the signifi-
cantly enriched in stage I on chromosome 7q are genes
involved in negative regulation of hydrogen peroxide-
mediated programmed cell death including HGF and
MET, and genes in androgen metabolic process including
CYP3A4, AKR1D1, and SHH, and mismatch repair com-
plex and single strand binding protein gene PMS2P5 and
PMS2P1, MCM7 and SSBP1. In addition, loss of chromo-
some 17p containing gene TP53 was found in five of ten
stage I HCCs, including three HCCs with whole arm dele-
tion of 17p and two HCCs with deletions of most part of
17p (17p11.2-p13.2 of 18.5 Mb and 17p11.2-pter of
18.3 Mb respectively). However, this association did not
reach statistical significance (Figure 4). TP53 deletion is
commonly associated with poor prognosis in neoplasm;
















Sanger census cancer gene
chr1:732,712-24,356,209 23,624 p36.33 - p36.11 Loss 20.00 375 7 TNFRSF14, PRDM16, RPL22, CAMTA1, SDHB, PAX7, MDS2
chr1:143,582,356-249,250,621 105,668 q21.1 - q44 Gain 80.00 1155 17
PDE4DIP, BCL9, ARNT, TPM3, MUC1, PRCC, NTRK1, SDHC,
FCGR2B, PBX1, ABL2, TPR, MDM4, ELK4, SLC45A3,
H3F3A, FH
chr4:80,505,114-115,297,840 34,793 q21.21 - q26 Loss 33.33 167 2 RAP1GDS1, TET2
chr5:0–46,279,735 46,280 p15.33 - p11 Gain 33.33 181 2 IL7R, LIFR
chr5:49,584,189-180,704,505 131,120 q11.1 - q35.3 Gain 26.67 846 11
IL6ST, PIK3R1, APC, PDGFRB, CD74, ITK, EBF1, RANBP17,
TLX3, NPM1, NSD1
chr7:0–57,675,692 57,676 p22.3 - p11.2 Gain 33.33 381 10
CARD11, PMS2, ETV1, HNRNPA2B1, HOXA9, HOXA11,
HOXA13, JAZF1, IKZF1, EGFR
chr7:61,750,617-159,138,663 97,388 q11.21-q36.3 Gain 40.00 757 12
SBDS, ELN, HIP1, AKAP9, CDK6, MET, SMO, CREB3L2,
KIAA1549, BRAF, EZH2, MLL3
chr8:13,403,518-29,636,237 16,233 p22 - p12 Loss 33.33 116 1 PCM1
chr8:46,967,935-145,730,376 98,762 q11.1 - q24.3 Gain 60.00 501 13
CHCHD7, TCEA1, PLAG1, NCOA2, NBS1, HEY1, CBFA2T1,
UBR5, COX6C, EXT1, MYC, NDRG1, RECQL4
chr9:0–45,983,160 45,983 p24.3 - p11.2 Loss 20.00 278 6 JAK2, CD274, NFIB, MLLT3, FANCG, PAX5
chr17:3,728,554-12,900,807 9,172 p13.2 - p12 Loss 40.00 205 5 USP6, TP53, PER1, GAS7, MAP2K5
chr17:13,297,102-18,590,696 5,293,594 p12 - p11.2 Loss 33.33 77 0
chrX:2,471,123-48,865,144 46,394 p22.33 - p11.23 Gain 20.00 257 7 ZRSR2, BCOR, KDM6A, SSX1, SSX4, WAS, GATA1
chrX:61,828,910-99,931,689 38,103 q11.1 - q22.1 Gain 26.67 156 4 MSN, MED12, NONO, ATRX




























chr1:142,898,654-143,481,059 582 q21.1 Loss 26.67 <0.001 0 has-mir-3118-2, has-mir-3118-2
chr2:127,807,016-127,821,014 14 q14.3 Loss 20.00 0.021 1 BIN1
chr2:141,745,577-141,790,622 45 q22.1 Gain 20.00 0.005 1 LRP1B
chr2:236,033,001-236,677,413 644 q37.2 Gain 20.00 0.005 1 AGAP1
chr3:196,726,226-196,756,289 30 q29 Loss 20.00 0.002 2 MFI2, MIF2-AS1
chr4:1,792,487-1,809,740 17 p16.3 Loss 33.33 <0.001 1 FGFR3 FGFR3
chr4:69,305,095-69,412,970 108 q13.2 Gain 40.00 <0.001 2 TMPRSS11E, UGT2B17
chr7:13,933,308-14,336,685 403 p21.2 Gain 46.67 <0.001 1 ETV1 ETV1
chr7:38,306,193-38,380,749 75 p14.1 Loss 33.33 <0.001 1 TARP
chr7:156,798,142-156,928,704 131 q36.3 Loss 46.67 <0.001 2 MNX1, LOC645249
chr8:145,737,034-145,741,006 4 q24.3 Loss 40.00 <0.001 1 RECQL4 RECQL4
chr9:139,390,677-139,425,667 35 q34.3 Loss 26.67 0.003 1 NOTCH1 NOTCH1
chr10:3,514,976-3,988,938 474 p15.2 - p15.1 Gain 26.67 0.008 1 KLF6
chr10:89,581,346-89,717,798 136 q23.31 Loss 20.00 0.021 3 CFL1P1, KLLN, PTEN PTEN
chr11:65,263,143-65,279,263 16 q13.1 Gain 26.67 0.003 1 MALAT1
chr16:2,104,905-2,135,150 30 p13.3 Loss 20.00 0.021 1 TSC2 TSC2
chr16:79,628,093-79,633,200 5 q23.2 Gain 20.00 0.003 1 MAF MAF
chr16:89,550,964-89,780,717 229753 q24.3 Gain 20.00 0.003 12
ANKRD11, SPG7, SNORD68, RPL13, CPNE7,
DPEP1, CHMP1A, C16orf55, CDK10,
SPATA2L, VPS9D1, LOC100128881
chr17:79,848,607-79,974,997 126390 q25.3 Loss 26.67 0.02 11
ALYREF, ANAPC11, NPB, PCYT2, SIRT7,
MAFG, MAFG-AS1, PYCR1, MYADML2,
NOTUM, ASPSCR1
ASPSCR1
chr18:14,827,524-15,293,288 465764 p11.21 Loss 53.33 <0.001 2 ANKRD30B, MIR3156-2
chr19:42,402,083-42,413,495 11412 q13.2 Loss 40.00 <0.001 1 ARHGEF1
















Figure 3 Frequency difference plot for gains and losses between groups in the comparison analysis. Comparison I: five of grade 1 and well
differentiated HCCs (Figure 3A) vs ten of grade 2, 3 or 4 and moderately or poorly differentiated HCCs (Figure 3B). Comparison II: ten of Stage I HCC
(Figure 3C) vs five of Stage II or III HCCs (Figure 3D). Comparison III: four of HCCs with vascular invasion (Figure 3E) vs eleven of HCCs without vascular
invasion (Figure 3F). Regions of loss are indicated by red bars and regions of gains by blue bars.
Liu et al. Molecular Cytogenetics 2014, 7:81 Page 7 of 15
http://www.molecularcytogenetics.org/content/7/1/81however, the follow-up information is not available for
most of the patients in this cohort.
In comparison analysis III, four HCCs with vascular in-
vasion (E, Figure 3) were compared with eleven HCCs
without vascular invasion (F, Figure 3). Significant copy
number aberrations associated with HCCs with vascular
invasion are gain of chromosome 5q (Table 6). Among the
genes in the significantly enriched in tumors with vascular
invasion on 5q are genes involved in BMP signaling path-
way including genes FST, ZFYVE16, RGMB, SMAD5,
EGR1, and NKX2-5 on chromosome 5q, and genes in-
volved in gamma-catenin binding including FER, APC,
and CTNNA1 on chromosome 5q.
Cluster analysis
The dendrogram was generated based on recurrent
chromosome aberrations of HCCs to construct genetic
subgroups which reflected their genetic similarities in
clusters (groups) (Figure 4). Chromosomal abnormalities
partitioned well with HCCs which formed a clad (indi-
cated by the arrow in Figure 4) with their paired non-
neoplastic specimens at the base of the dendrogram. In
the HCC clad, grade 1 and well differentiated HCCs
were distributed as basal branches, while most of higher
grade and less differentiated HCCs formed more orga-
nized clusters. Gain of 1q (80%) was most common and
found in all HCCs with grade 2–4 and three of 5 HCCs
with grade 1. The cluster of HCCs with gains of 1q, 8q,
and trisomy 5 were associated with higher grades (2–4)
and moderate to poor tumor differentiation, which
were consistent with the results of comparison analysis
(Tables 4, 5 and 6).
Discussion
In this study, our data demonstrated the feasibility of
whole genome microarray analysis using FFPE samples of
hepatocellular carcinoma, as all of specimens used in this
study were FFPE samples, including HCCs and paired
non-neoplastic cirrhotic liver tissues. Using FFPE speci-
mens for molecular and genomic studies are technicallychallenging due to the chemical crosslinks and degrad-
ation of DNA and RNA in these samples. However, it is
important to establish the methods for molecular
characterization using genomic approaches with FFPE
tissue samples as they make up a vast archive of patho-
logically well-characterized clinical samples and are an
immense resource that can be used for conducting bio-
marker investigation.
Contrary to many previous copy number aberration
studies of HCC using conventional CGH with 10–
20 Mb resolution or BAC array with 1–2 Mb resolution
for genetic characterization of HCCs with various or un-
known etiologies (Table 7) [9-14], this study focuses on
HCV associated HCCs using high density whole genome
oligo microarray analysis which provides higher reso-
lution (>2 kb) to facilitate gene discovery. In addition,
the levels of amplifications involving known oncogenic
genes are readily detected. The copy number amplifica-
tion can also be calculated based on the values of log2
ratio and tumor cellularity, as in specimen HCC01
which had 7-copy amplification of MDM4 and PIK3C2B
(Figure 1). MDM4 is known to contain a p53 binding
domain at the N-terminus and a RING finger domain at
the C-terminus, and has been shown to interact with
E2F1 [15], MDM2 [16,17] and P53 tumor suppressor
protein [18], and overexpress in a variety of human can-
cers. PIK3C2B belongs to the phosphoinositide 3-kinase
(PI3K) family which play certain roles in signaling path-
ways involved in cell proliferation, oncogenic transform-
ation, cell survival, cell migration, and intracellular
protein trafficking. Co-amplification of the adjacent
genes may provide an additional growth advantage in
HCC. In addition, PIK3C2B may serve as a potential
therapeutic target. The protein encoded by PIK3C2B
was demonstrated to play an essential role in HCV
propagation in human HCC cells, and knockdown of
PIK3C2B abolished HCV propagation in the cell [19].
Clonal chromosomal abnormalities were detected
in all HCC samples but not found in their paired
non-neoplastic tissues (Figure 4), demonstrating that
Table 4 Result summary of the comparison analysis between grade 1/well differentiated HCCs and grade 2-4/moderately or poorly differentiated HCCs














p-value Numberof genes Sanger census cancer genes
chr1:146,319,961-159,188,358 q21.1 - q23.2 Gain 12,868 40 100 0.022 261 BCL9, ARNT, TPM3, MUC1, NTRK1
chr8:46,967,935-67,313,267 q11.1 - q13.1 Gain 20,345 0 60 0.044 76 CHCHD7, TCEA1, PLAG1
chr11:113,937,346-114,144,024 q23.2 Gain 207 60 0 0.022 1 (ZBTB16)



























of genes Sanger census cancer genes
chr7:13,933,308-14,289,034 p21.2 Gain 356 70 0 0.026 2 ETV1
chr7:54,910,410-55,228,621 p11.2 Gain 318 70 0 0.026 1 EGFR
chr7:61,750,617-159,138,663 q11.21-q36.3 Gain 97,388 60 0 0.044 757
SBDS, ELN, HIP1, AKAP9, CDK6, MET, SMO,
CREB3L2, KIAA1549, BRAF, EZH2, MLL3
















Table 6 Result summary of the comparison analyses between HCCs with vascular invasion and without vascular invasion (Figure 3E and F)









p-value Numberof genes Sanger census cancer genes
chr5:49,584,189-180,704,505 q11.1 - q35.3 Gain 131,120 75 9.091 0.033 846
IL6ST, PIK3R1, APC, PDGFRB, CD74, ITK,
















Figure 4 The dendrogram generated from cluster analysis. Genetic subgroups shown as clads/clusters were labeled with shared chromosomal
aberrations on the branches leading to the clades or the HCC specimen. Chromosomal abnormalities partitioned with HCCs and formed a clad that
was indicated by the arrow. Their paired non-neoplastic specimens were at the base of the dendrogram without clonal chromosomal aberrations
detected. Clinical and pathological features associated with each HCC were listed in the table next to it.
Liu et al. Molecular Cytogenetics 2014, 7:81 Page 11 of 15
http://www.molecularcytogenetics.org/content/7/1/81chromosomal copy number aberrations detected by whole
genome microarray analysis were tumor-associated som-
atic changes and may serve as good genetic markers to
distinguish tumors from non-neoplastic cirrhotic nodules.
The frequent chromosomal aberrations (>5 Mb) found
in this study, including gains of 1q and 8q and loss of
1p, 4q, 8p, 9p, and 17p, were largely consistent with pre-
vious reports for HCCs with various etiologies, including
virus-associated and non-viral HCCs (Table 7) [9-14].
Similar pattern of chromosomal imbalances with differ-
ent etiology suggests a common basic state for HCC de-
velopment, most likely the chronic process of cirrhosis
due to non-specific inflammatory and regenerative pro-
cesses. However, frequent gains of chromosomes 5 (33%)
and/or 7 (33-40%) found in this cohort (Table 2, Figures 2Table 7 Comparison of frequencies of major gains and losses
Method Etiology
Chromosomal gain (frequenc
1q 5p 5q 7p 7q 8
Conventional CGH HCV, HBV, or non-viral 46 27 <5 <5 <5 6
BAC or Oligo CGH HCV, HBV, or non-viral >25 NA* NA NA NA >
Conventional CGH HCV, HBV, or non-viral 49 <5 6 13 15 5
Conventional CGH HCV or HBV 46 <5 <5 <5 <5 4
Conventional CGH HCV only 46 5 5 9 9 3
Conventional CGH HCV only 79 16 11 16 11 3
oligo CGH HCV only 80 33 27 33 40 6
*NA - note available.and 4) have not been reported previously as common
chromosomal aberrations in HCC (Table 7), suggesting
that trisomy 5 and/or trisomy 7 could be the specific aber-
rations for HCV associated HCCs and future studies are
warranted.
In addition, smaller deletions (3.9 – 582 kb) were
identified to be statistically significant in this HCV-
HCC cohort. These deletions contained known cancer
genes based on the Sanger Census cancer gene list, in-
cluding FGFR3, RECQL4, NOTCH1, PTEN, TSC2, and/
or ASPSCR1 (Table 3) which suggested their roles as
tumor suppressor genes in the development of HCC.
These genetic alterations were undetected by previous
studies with conventional CGH and BAC arrays, most
likely due to the low resolution of the analyses.of genomic regions from this study and previous reports
y, %) Chromosomal loss (frequency, %)
References
q 17q 20q 1p 4q 6q 8p 9p 17p
9 46 31 35 42 15 58 27 31 [12]
25 >25 NA NA >25 >25 >25 >25 >25 [11]
5 13 12 18 33 33 55 13 22 [13]
1 37 <5 24 39 61 44 24 <5 [14]
1 43 27 37 48 23 28 9 37 [10]
7 16 11 32 53 21 32 11 79 [9]
0 <5 <5 20 33 7 33 20 40 This study
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can have both tumor suppressive and oncogenic proper-
ties. It was shown that FGFR3 signal can limit tumor
growth with epithelial origin. Therefore, for tumors of
epithelial origin, loss of FGFR3 was found in higher
grade tumor while activating mutations of FGFR3 were
found in benign or low grade tumor with good prognosis
[20]. Although little is known on FGFR3 actions in
HCC, FGFR3 deletion was found mostly in grade 2–3
HCC in this cohort, indicating FGFR3 as a tumor sup-
pressor gene in HCC and is associated with HCC of
higher grade. FGFR3 oncogenic property is crucial for
targeted therapy involving specific tyrosine kinase inhibi-
tors. Loss of NOTCH1 resulted in a continuous prolifera-
tion of hepatocytes and nodular regenerative hyperplasia
in conditional NOTCH1 knockout mouse model [21].
PTEN as a tumor suppressor, negatively regulating AKT/
PKB signaling pathway by preferentially dephosphorylates
phosphoinositide substrates, is mutated in a large number
of cancers including 40-50% of human liver cancers such
as HCC and cholangiocarcinoma [22]. TSC2 is a tumor
suppressor and is able to stimulate specific GTPases. Loss
of TSC2 leads to activation of MTOR and downstream
signaling elements, causes endoplasmic reticulum (ER)
stress, activates the unfolded protein response, and results
in tumor development [23]. TSC2 deletions were found in
HCV-associated HCC with grade 2–3 and moderate dif-
ferentiation and without vascular invasion in this cohort.
This finding is consistent with the finding that decreased
TSC2 expression was found to be significantly correlated
with higher grade and poor prognosis, but is inconsistent
with the association with vascular invasion in a recent
study [24]. The discrepancy may be explained by the
population difference as all HCC cases are soly HCV asso-
ciated in this study while the majority cases in Huang’s
study were HBV associated HCCs with only two HCV-
associated HCCs [24]. RECQL4, a DNA helicase that be-
longs to the RecQ helicase family, has not been previously
recognized to be involved in HCC development. This
study also showed that deletions involving whole gene
ASPSCR1 (alveolar soft part sarcoma chromosome re-
gion, candidate 1) were detected in HCC with statistical
significance. The deletions of ASPSCR1 most likely re-
sulted in the loss of function and decreased expression
of ASPSCR1, suggesting its role as a potential tumor
suppressor gene in the development of HCC. In
addition, loss of function and decreased expression of
ASPSCR1 has also been implicated in synthetic lethal
interactions in cancer [25]. Gene ASPSCR1 is relatively
uncharacterized. An ASPSCR1–TFE3 fusion protein
due to an unbalanced translocation der(17) t(X;17) has
been associated with alveolar soft-part sarcoma (ASPS),
which resulted in unregulated transcription of TFE3
and TFE3-regulated genes and a truncated allele ofASPSCR1 with loss of function [26]. Future studies of
the role of ASPSCR1 in HCC are warranted.
There is great interest in identifying genetic markers
of HCC that qualify for risk stratification. Most previ-
ous studies did not have detailed pathological data and
correlation analysis between the genetics data and
pathological data have not been conducted. We found
several correlations between genetic data and clinico-
pathological data by comparison analysis. Gain of
1q21.1-q23.2 and gain of 8q11.1q13.1 were significantly
associated with grade 2–4 and moderately or poorly
differentiated HCCs (Table 4), including genes that are
significantly enriched in positive regulation of nuclear
factor-kappa B (NF-kappaB) transcription factor activity
and regulation of chemokine production. This result
suggests that NF- kappaB plays a role in the progres-
sion of HCC. The NF-κB transcription factor family is
known to play an important role in many immune and
inflammatory responses, and inflammation is consid-
ered a hallmark of cancer [27]. Enhanced expression of
inflammatory cytokines and chemokines as key coordi-
nators of the cross talk between hepatocytes and acti-
vated hepatic stellate cells was shown to be crucial in
HCC development and progression, either by direct sig-
naling or by recruiting immune cells [27,28] .
Comparison analysis also showed that gain of chromo-
some 5q was significantly associated with HCCs with
vascular invasion (Table 6), which is a poor prognostic
indicator for tumor spread. Gene enrichment analysis
detected genes in bone morphogenetic proteins (BMP)
signaling pathway including genes FST, ZFYVE16,
RGMB, SMAD5, EGR1, and NKX2-5 on chromosome 5q
and in gamma-catenin binding including FER, APC, and
CTNNA1 on chromosome 5q (Table 6), suggesting that
copy number gain and increased expression of BMP sig-
naling may contribute to tumor progression and inva-
sion. BMPs comprising the largest family within the
TGF-β superfamily, originally reported as factors that in-
duce bone and cartilage formation and development,
have been shown to be critical for cancer development
and progression [29]. Elevated expression levels of BMPs
have been detected in many types of solid tumors, and
BMP signaling pathway are intimately involved in both
the inhibition and promotion of cancer progression [30].
A similar dual role for the superfamily member TGFβ is
known to act as a tumor suppressor during the initial
steps of tumorigenesis, but later found to promote
tumor progression and invasion [31].
Furthermore, copy number variant (CNV) burden in
terms of number of observed acquired CNV events
(>5 Mb) in each case was greater in HCCs with grade
2–4 or moderate or poorly differentiated tumors (aver-
age 7.1 CNVs per case) compared to HCCs with grade 1
and well differentiated tumors (average 3.8 CNVs per
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vanced HCCs.
HCC has gender disparity with an increased frequency
in males. Copy gain involving androgen receptor (AR)
were observed in five HCCs of male patients in this co-
hort, including gain of Xq in four HCCs, and a gain con-
taining only gene AR in one HCC. In addition, a gain
containing the promoter region and first two exons of
AR was observed in one HCC. It has been proposed that
higher activity of androgen pathway functions as a
tumor-promoting factor in male hepatocarcinogenesis,
as knockout of AR expression in hepatocytes delayed the
development of N’,N’-diethylnitrosamine (DEN)-induced
HCC [32].
Conclusions
This study has provided a detailed map of genomic aber-
rations occurring in HCV-associated HCC and has sug-
gested candidate genes. As many frequent gains and
losses are also common in HCCs with various etiologies,
gains of chromosomes 5 and/or 7 appeared to be the
specific aberrations for HCV-associated HCCs. While
gain of 1q21.1-q23.2 and gain of 8q11.1q13.1 are signifi-
cantly associated with grade 2–4 and moderately or
poorly differentiated HCCs, gain of chromosome 7q is
significantly associated with stage I HCCs, and gain of
chromosome 5q was significantly associated with HCCs
with vascular invasion which is poor prognosis indicator
for tumor spreading. NF- kappaB and BMP signaling
pathways were indicated for HCC development and pro-
gression. This study demonstrated that genomic micro-
array test can be used to distinguish HCC from non-
neoplastic cirrhotic nodules and to identify signaling
pathways involved in HCC development and prognostic
factors associated with HCC progression using patho-
logically characterized FFPE samples. Our data support
the utility of genomic microarray test for the diagnosis,
risk stratification, and pathogenic studies of HCC.
Methods
FFPE tissue specimens
The pathological archives of representative number of
hepatocellular carcinoma (HCC) were retrospectively
reviewed and selected from the Department of Pathology
at the University of Washington Medical center, includ-
ing 15 HCV-associated HCC in cirrhotic livers, all from
explanted liver specimens. The study protocol was
reviewed and approved by the institutional review boards
(University of Washington, Human Subjects Division). All
specimens used in this study were formalin-fixed paraffin-
embedded (FFPE) tissue specimens. Hematoxylin and
eosin stained slides were reviewed to confirm the diag-
nosis and to grade and subclassify the HCC accordingly
[33]. In addition, both cancer tissues and nearbycirrhotic non-neoplastic tissues were processed for the
genetic characterization for 10 of 15 HCV-associated
HCC cases, while in five of 15 cases, only HCC tissues
were available for analysis.
We reviewed the clinical records of these patients and
retrieved the data on demographic characteristics and
clinical outcomes (Table 1). The tumor-node-metastasis
(TNM) staging system of American Joint Committee on
Cancer (Edition 7) was used to determine the T stage of
the tumors [34].
DNA extraction
Tumor and non-neoplastic areas were identified in H &
E-stained slides and corresponding areas were dissected
with a scalpel from the paraffin slides. Genomic DNA
from FFPE tissue was extracted using manufacture rec-
ommended procedure (Agilent Technologies, Santa
Clara, CA, USA) which is based on the method de-
scribed by van Beers et al. [35] using the Qiagen
DNeasy Blood & Tissue Kit (Qiagen Inc, Valencia, CA,
USA). This procedure is optimized for 5 sections of 4–5
micron FFPE section containing about 1 cm2 of tissue.
The concentration and the quality of genomic DNA
were determined using Spectrophotometer NanoDrop
ND-1000 (Thermo Fisher Scientific Inc., Wilmington,
DE, USA).
Genomic microarray analysis
Purified genomic DNA and the normal control refer-
ence DNA were then digested with restriction enzymes,
labeled separately with contrasting fluorescence, and
competitively hybridized to the custom designed high
density oligonucleotide microarray as specified by the
manufacturer (Agilent Technologies, Santa Clara, CA,
USA). Chromosomal microarray analysis was per-
formed on genomic DNA using the Agilent SurePrint
G3 Cancer CGH + SNP 4x180K Array, a cancer-specific
CGH + SNP microarray designed by Cancer Genomics
Consortium (CGC) (http://www.chem-agilent.com/pdf/
5990-9183en_lo_CGH+SNP_Cancer.pdf ). Arrays were
scanned using a DNA Microarray Scanner with SureS-
can High-Resolution technology (Agilent Technologies,
Santa Clara, CA, USA). Whole genome microarray data
were analyzed using Agilent CytoGenomics 2.5 to iden-
tify copy number changes. The global ADM2 algorithm
with a threshold 6.0 and aberration filter for a mini-
mum of five probes per region were applied. The CGH
array data were also evaluated independently with sec-
ond software Nexus Copy Number 7.5 (BioDiscovery,
Inc. Hawthorne, CA, USA) to confirm the copy number
changes identified by Cytogenomics. The log2R ratios
provide information regarding copy number. These
were determined by visual inspection. Genomic linear
positions were given relative to NCBI build 37 (hg19,
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tect copy number changes that include at least 5 probes
(markers) for deletions or duplications.
Statistical analysis
To identify nonrandom gains and losses across multiple
samples that are more likely to drive cancer pathogen-
esis, genetic aberrations in this cohort were evaluated
for their statistically significance using statistical ap-
proaches with STAC algorithm adopted in Nexus 7.5
(BioDiscovery, Inc. Hawthorne, CA, USA). Significance
Testing for Aberrant Copy number (STAC) is a method
for testing the significance of DNA copy number aberra-
tions across multiple microarray experiments to identify
a set of aberrations that are aggregate in the overlapping
regions such that it would not occur randomly [36]. The
method applies two statistics, the frequency of aberra-
tion at a location across the entire sample set and p-
value assigned to each location on the genome by using
a multiple testing corrected permutation approach. The
p-Value cut-off of 0.05 and the Aggregate % cut-off of
20% were used in the analyses.
Comparison analysis was conducted to correlate re-
current genetic alterations observed with clinical and
pathologic data using Nexus 7.5 (BioDiscovery, Inc.
Hawthorne, CA, USA). Statistical comparison using
Fisher Exact test was performed to determine the
p-value of certain genetic aberration in one group vs
the other group in comparison. Scores exceeding the
significant threshold with p-Value cut-off of 0.05 and
below the differential threshold cut-off of 25% were
used in the analyses. Comparisons between different
groups of tumors based on the pathologic features were
conducted to detect genomic regions that were signifi-
cant different between the groups in a comparison
based on the p-value. The factor sets compared in this
study included tumor grade and differentiation, tumor
stage, and vascular invasion.
Using significant common aberrations identified by
comparison analysis, gene enrichment analysis on these
selected regions of interest was conducted to attain the
biological implications of these aberrations using Nexus
7.5 (BioDiscovery, Inc. Hawthorne, CA, USA). Enrich-
ment analysis identifies gene ontology (GO) terms that
are significantly overrepresented and identifies the
genes annotated with these terms within this aberrant
region [37,38].
Clustering analysis
The genetic similarity between the tumor samples were
evaluated using parsimony analyses by clustering similar
recurrent aberration of genetic data using PAUP, version
3.1.1 [39,40] to generate a dendrogram that illustrated
the arrangement of the clusters. The identified clusterswith recurrent genetic aberrations were correlated with
clinical and pathological features.
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